Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China

Reuters2025-12-24

<a href="https://laohu8.com/S/LYPHF">Luye Pharma</a> Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China

Luye Pharma Group Ltd. announced that its subsidiaries have entered into an agreement with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd., a subsidiary of Jiangsu Nhwa Pharmaceutical Co., Ltd. Under the agreement, Nhwa is granted exclusive commercialization rights for three long-acting injectable antipsychotics—Rykindo (risperidone microspheres for injection (II)), Ruibailai (paliperidone palmitate injection (II)), and Meibirui (paliperidone palmitate injection)—in the Chinese Mainland. The products are indicated for the treatment of schizophrenia. The agreement has a ten-year term, with Nhwa paying a one-time, non-refundable licensing fee of USD 20 million. Luye Pharma will retain product ownership, marketing authorizations, and intellectual property rights, and will remain responsible for manufacturing and supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251224-11966902), on December 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593784274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593784274","market":"nz","top_or_hot":-1,"title":"Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LYPHF\">Luye Pharma</a> Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Luye Pharma Group Ltd. announced that its subsidiaries have entered into an agreement with <a href=\"https://laohu8.com/S/002262\">Jiangsu Nhwa</a> Hexin Pharmaceutical Marketing Co., Ltd., a subsidiary of Jiangsu Nhwa Pharmaceutical Co., Ltd. Under the agreement, Nhwa is granted exclusive commercialization rights for three long-acting injectable antipsychotics—Rykindo (risperidone microspheres for injection (II)), Ruibailai (paliperidone palmitate injection (II)), and Meibirui (paliperidone palmitate injection)—in the Chinese Mainland. The products are indicated for the treatment of schizophrenia. The agreement has a ten-year term, with Nhwa paying a one-time, non-refundable licensing fee of USD 20 million. Luye Pharma will retain product ownership, marketing authorizations, and intellectual property rights, and will remain responsible for manufacturing and supply.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251224-11966902), on December 24, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-24 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LYPHF\">Luye Pharma</a> Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Luye Pharma Group Ltd. announced that its subsidiaries have entered into an agreement with <a href=\"https://laohu8.com/S/002262\">Jiangsu Nhwa</a> Hexin Pharmaceutical Marketing Co., Ltd., a subsidiary of Jiangsu Nhwa Pharmaceutical Co., Ltd. Under the agreement, Nhwa is granted exclusive commercialization rights for three long-acting injectable antipsychotics—Rykindo (risperidone microspheres for injection (II)), Ruibailai (paliperidone palmitate injection (II)), and Meibirui (paliperidone palmitate injection)—in the Chinese Mainland. The products are indicated for the treatment of schizophrenia. The agreement has a ten-year term, with Nhwa paying a one-time, non-refundable licensing fee of USD 20 million. Luye Pharma will retain product ownership, marketing authorizations, and intellectual property rights, and will remain responsible for manufacturing and supply.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251224-11966902), on December 24, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDLbRHJDq:1","article_id":"2593784274","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593784274","pubTimestamp":1766566909,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Luye Pharma Group Ltd. announced that its subsidiaries have entered into an agreement with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd., a subsidiary of Jiangsu Nhwa Pharmaceutical Co., Ltd. Under the agreement, Nhwa is granted exclusive commercialization rights for three long-acting injectable antipsychotics—Rykindo , Ruibailai , and Meibirui —in the Chinese Mainland. The products are indicated for the treatment of schizophrenia. The agreement has a ten-year term, with Nhwa paying a one-time, non-refundable licensing fee of USD 20 million. Luye Pharma will retain product ownership, marketing authorizations, and intellectual property rights, and will remain responsible for manufacturing and supply.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK0239":"医药制造","002262":"恩华药业","BK0188":"融资融券","BK1191":"制药","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK1606":"中医药概念","BK0070":"员工持股","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","02186":"绿叶制药"},"translate_title":"绿叶制药授予Nhwa三种长效抗精神病药物在中国的独家商业化权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002262":0.9,"02186":0.9},"content_text":"Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China\n    \n\n        Luye Pharma Group Ltd. announced that its subsidiaries have entered into an agreement with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd., a subsidiary of Jiangsu Nhwa Pharmaceutical Co., Ltd. Under the agreement, Nhwa is granted exclusive commercialization rights for three long-acting injectable antipsychotics—Rykindo (risperidone microspheres for injection (II)), Ruibailai (paliperidone palmitate injection (II)), and Meibirui (paliperidone palmitate injection)—in the Chinese Mainland. The products are indicated for the treatment of schizophrenia. The agreement has a ten-year term, with Nhwa paying a one-time, non-refundable licensing fee of USD 20 million. Luye Pharma will retain product ownership, marketing authorizations, and intellectual property rights, and will remain responsible for manufacturing and supply.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251224-11966902), on December 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593784274","isCrawlerRequest":true}